Bybit has added three U.S. stock perpetual contracts to its lineup today: INTUUSDT for Intuit, RAMUSDT for Roundhill T-Rex 2x DRAM ETF, and DJTUSDT for Trump Media & Technology Group. According to Odaily, all three contracts support leverage of up to 25x. The exchange is also rolling out a limited-time fee promotion alongside the launch. During the promotional period, maker fees for limit orders are set at 0%, while taker fees for market orders are discounted by 50%. The update expands Bybit’s U.S. equity-linked perpetual offerings with three newly listed products announced on the same day.

Storage and semiconductor names moved higher in U.S. premarket trading on Aug. 25, according to market data from BIT (bit.com). Intel led the listed gainers with a 2.29% rise, followed by SK Hynix ADR at 2.11%. Western Digital rose 1.82%, Sandisk gained 1.8%, AMD added 1.77%, Micron Technology climbed 1.7%, Seagate Technology advanced 1.5%, and Nvidia was up 1.1%. The move covered both chipmakers and storage-related stocks, pointing to broad strength across the segment in premarket action. BlockBeats cited the data in a market update published the same day.

Former U.S. House Speaker Nancy Pelosi has disclosed new stock purchases in Bloom Energy and Intel, according to an official filing submitted to the Clerk of the House of Representatives. The filing shows two Bloom Energy transactions, one on July 24 and another on July 28, covering both common shares and call options. Pelosi reported buying 10,000 Class A common shares of Bloom Energy on July 24, valued in a disclosure range of $1 million to $5 million, along with 100 call option contracts with a $100 strike price expiring on June 17, 2027, also valued at $1 million to $5 million. On July 28, she disclosed another purchase of 5,000 common shares valued at $500,000 to $1 million and 100 additional call options with the same strike price and June 2027 expiry, valued at $500,000 to $1 million. In total, the filing points to 15,000 BE shares and 200 call options, with the overall Bloom Energy position disclosed in a range of $3 million to $12 million. The same filing also shows a July 24 Intel purchase of 10,000 common shares and call options with a $50 strike price expiring on June 17, 2027.

Techub News says stablecoin infrastructure company Crossmint has expanded its regulatory footprint into Canada. The company has registered with the Bank of Canada as a payment service provider under the Retail Payment Activities Act (RPAA), and it has also registered with the Financial Transactions and Reports Analysis Centre of Canada (FINTRAC) as a money services business (MSB). Crossmint said the move is aimed at expanding its regulated stablecoin rails.

US stocks tied to semiconductors, memory and optical communications moved lower in Monday premarket trading on Aug. 24, according to market data from BIT (bit.com). Chip names broadly posted modest losses, including Lam Research (LRCX), Intel (INTC), Applied Materials (AMAT), and Arm (ARM). Memory-related stocks also traded lower, with SK Hynix (SKHY), Micron Technology (MU), Western Digital (WDC), SanDisk (SNDK), and Seagate Technology (STX) all in the red. Optical communications names saw some of the steeper declines in the group. Astera Labs (ALAB), Coherent (COHR), Credo (CRDO), and Lumentum (LITE) each fell, while Applied Optoelectronics (AAOI) dropped 11.66%, the largest decline among the stocks listed in the report.

The US Treasury’s decision to expand its buyback operations for longer-dated Treasuries has sparked a fresh debate over liquidity, bond-market stress, and the purchasing power of the dollar. Beginning Sept. 9, the Treasury will raise the cap on each repurchase operation for 10-year to 30-year US government bonds from $2 billion to at least $4 billion. Officials said the move is aimed at improving market liquidity and does not qualify as quantitative easing, stressing that only the Federal Reserve can expand the monetary base. Robert Kiyosaki, author of Rich Dad Poor Dad, rejected that distinction. He argued that more Treasury buybacks still mean more dollar liquidity entering the system and described the step as another round of “fake” money creation. Kiyosaki also pointed to weakness in the US Dollar Index, saying the move reflects inflation concerns and leaves cash savers exposed as purchasing power erodes. He repeated his long-held call for investors to hold scarce assets such as gold, silver, and Bitcoin, while also mentioning quality real estate. The debate comes as US national debt has surpassed $40 trillion and market attention remains fixed on long-dated Treasury yields, the dollar’s direction, and inflation expectations.

U.S. stocks finished higher on Friday, Aug. 22, with all three major indexes ending in positive territory, according to BlockBeats. The Dow Jones Industrial Average was preliminarily up 0.98%, while both the S&P 500 and the Nasdaq gained 0.43%. Among major stocks, Tesla (TSLA.O) rose 5.14% and hit a one-month high. Oracle (ORCL.N) added 3.11%, and SpaceX (SPCX.O) climbed 2.22%. On the downside, Intel (INTC.O) fell 2.24% and Nvidia (NVDA.O) slipped 0.98%. Crypto-related stocks also stayed strong. MicroStrategy-related ticker MSTR gained 6.10%, while CRCL rose 5.16%. Coinbase (COIN) posted one of the largest advances in the group, up 8.20%. BMNR climbed 5.84%, SBET added 4.22%, and PURR rose 4.96%.

JPMorgan said in an Aug. 19 research note that Moderna and Merck’s individualized neoantigen therapy, referred to as INT, met its primary endpoint in adjuvant melanoma, with recurrence-free survival showing a significant improvement. The key secondary endpoint, distant metastasis-free survival, also met the bar. Even so, the bank argued the result was widely expected and had already been reflected in Moderna’s share price before the update was released. The firm kept its Underweight rating and a $40 price target on Moderna, versus a current share price of $63 cited in the note, implying 36% downside. JPMorgan’s view is that the clinical success of INT in adjuvant melanoma is no longer the main valuation question. Instead, the next leg of value depends on whether the therapy can show similar efficacy across a broader set of tumor types. JPMorgan said it had already assigned an 85% probability of success to the phase III melanoma study, based on prior phase IIb data and the biological rationale of the approach in cancer immunotherapy. The bank added that adjuvant melanoma is a relatively small indication, and that Moderna’s roughly $25 billion market value already includes expectations for approval in this setting. It said future data in non-melanoma indications will be more important for the company’s valuation.